Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-13
2005-12-13
Henley III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06974820
ABSTRACT:
Methods are disclosed using Trospium Chloride, an antimuscarinic smooth muscle relaxant, for the treatment of urinary incontinence, and other disorders, while avoiding the concomitant liability of adverse side effects associated with other antimuscarinic drugs.
REFERENCES:
patent: 3480626 (1969-11-01), Pfleger et al.
patent: 5998430 (1999-12-01), Schwantes et al.
patent: 6482837 (2002-11-01), Wood
patent: 2002/0010216 (2002-01-01), Rogosky et al.
patent: 2003/0144352 (2003-07-01), Cammarata et al.
Ulshofer, et al., Clin. Drug Invest. 2001: 21(8): 563-569.
Pharmacology & Toxicology 1999, 85, 299-304; Svane Beckmann-Knopp et al.; “Inhibitory Effects of Trospium Chloride on Cytochrome P450 Enzymes in Human Liver Microsomes”.
Bertholdt H. et al., Arzneimittel-Forsch, 17; 719-726 no date available.
Biochemical Pharmacology, vol. 22, pp. 3099-3108. Pergamon Press, 1973; Yung-Chi Cheng et al.; “Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor which causes 50 per cent Inhibition (I50) of an Enzymatic Reaction”.
The Lancet; vol. 338; Aug. 10, 1991 pp. 344-345; M.J. Connolly et al.; “Torsades de pointes ventricular tachycardia and terodiline”.
Chrysalis; P.a. Gayheart-Walsten, et al.; “Effects of a New Non-Sedating Antihistamine on QTc Interval in a Newly Developed Guinea Pig Model”, no date available.
Journal of Cardiovascular Pharmacology; 37: 607-618; 2001; Gary A. Gintant et al.; “The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis”.
Dig Dis 1992; 10: 38-45; Juha M. Gronroos et al.; “Cholinergic Hypothesis of Alcoholic Pancreatitis”.
Clinical Pharmacology & Therapeutics Jul. 1996 ; 07019901; pp. 89-98; Kenneth Hartigan-Go, MD et al.; “Stereoselective Cardiotoxic Effects of Terodiline”.
Abstracts 487-488; 85A; Hofner et al.; “Tolerability and Efficacy of Trosplum Chloride in a Long-Term Treatment (52 weeks) in Patients with Urge-Syndrome: A Double-Blind, Controlled, Multicentre Clinical Trial”, no date available.
Ital Heart J. Suppl. 2000; 1 (3): 419-422; Imperadore et al.; “Arresto cardiaco da fibrillazione ventricolare in corso di pancreatitte acuta biliare: descrizione di un caso clinico e ipotesi eziopatogentiche”.
Page from Medscape from WEBMD; Rhythm disorders in gallstones; no date provided, http://intapp.medscape.com/ps/medlineapp/getdoc?ord=1&searchid=15&have-local-holdings-file=1&local_journal-only-O&searchstring-%22arrhythmia%22+and+cholethiasis%22.
British Journal of Pharmacology (2000) 131, 245-254; Stephen E. Jones et al.; “Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K+ currents and action potentials”.
The Journal of Pharmacology and Experimental Th rapeutics; vol. 247, No. 3; pp. 867-872; James F. Kachur et al.; “R and S Enantiomers of Oxybutynin: Pharmacological Effects in Guinea Pig Bladder and Intestine”, no date provided.
Pharmacology & Toxicology 1998, 82, 161-166; Eeva Lukkari et al.; “Cytochrome P450 Specificity of Metabolism and Interactions of Oxybutynin in Human Liver Microsomes”.
British Journal of Urology (1995), 75, 452-456; H. Maderscacher et al.; “Trospium Chloride Versus Oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia”.
The Journal of Urology; vol. 148, 595-597, Aug. 1992; Charlotte A. Massad et al.; “The Pharmacokinetics of Intravesical and Oral Oxybutynin Chloride”.
The Journal of Pharmacology and Experimental Therapeutics; vol. 256, No. 2; L.Noronha-Blob et al.; “Enantiomers of Oxybutynin: In Vitro Pharmacological Characterization at M1, M2 and M3 Muscarinic Receptors and in Vivo Effects on Urinary Bladder Contraction,Mydriasis and Salivary Secretion in Guinea Pigs”, no date provided.
Bur J Clin Pharmacol (1994) 47: 337-343; A. Pietzko et al.; “Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers”.
Drug Metabolism and Disposition vol. 26, No. 4 pp. 289-293; Hans Postlind et al.; “Tolterodine, A New Muscarinic Receptor Antagonist, Is Metabolized”, no date provided.
The Journal of Pharmacology and Experimental Therapeutics; vol. 290, No. 3; pp. 1417-1426; Shuba et al.; “Action Potentials, Contraction, and Membrane Currents in Guinea Pigs Ventricular Preparations Treated with the Antispasmodic Agent Terodiline”, no date provided.
Arzneimittel-Forschung/Drug Research 48 (11), 10, 1012-1018 (1998); Smith et al. “Comparison of the Antimuscarinic and Antispasmodic Actions of Racemic Oxybutynin and Desethyloxbutynin and Their Enantiomers with Those of Racemic Terodiline”.
Page from Medscape from WEB MD; “Effects of Tolterdoine, Trospium Chloride, and oxybutynin on the central nervous system”, no date provided, http://intapp.medscape.com/px/medlineapp/getdoc7ord=4&searchid=3&have_local_holdings_file=1&local_journals_only=0&searchstring=trospium.
Clin Drug Invest 23(6); 395-404, 2003; Diefenbach et al.; “Randomised, Double-Blind Study of the Effects of Oxybutynin, Tolterodine, Trospium Chloride and Placebo on Sleep in Health Young Volunteers”.
Bridge Pharma, Inc.
Henley III Raymond J.
Nields & Lemack
LandOfFree
Methods for treating urinary incontinence and other... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating urinary incontinence and other..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating urinary incontinence and other... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3501809